# Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

> **NCT01379209** · PHASE1,PHASE2 · COMPLETED · sponsor: **Regimmune Corporation** · enrollment: 68 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** RGI-2001
- **DRUG:** Calcineurin Inhibitors
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Conditioning Regimen
- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **DRUG:** Methotrexate
- **DRUG:** Mofetil Mycophenolate
- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT01379209
- **Lead sponsor:** Regimmune Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-06
- **Final completion:** 2017-04
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01379209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01379209, "Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01379209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*